Human Milk Proteins Through Precision Fermentation
Precision fermentation—long used to produce insulin, enzymes, and rennet—is now being deployed by food‑tech startups to create bioidentical human milk proteins without relying on animals. By inserting specific DNA sequences into microbes, companies can ferment targeted molecules at scale.
In infant nutrition, the focus is shifting to proteins naturally present in breast milk, with lactoferrin emerging as a leading target. Lactoferrin, an iron‑binding whey protein associated with immune and gut health, is abundant in human milk and has clear antimicrobial and immune‑modulating roles.
Elena Medo, CEO of Leonie Health PBC, noted: “Lactoferrin is attractive because it’s abundant in human milk and has clear antimicrobial and immune-modulating functions.” However, she cautions that the protein’s performance depends on the full biological system of breast milk. “Its effects depend on the full living matrix of human milk… lactoferrin doesn’t act alone.” Despite this complexity, investor interest in fermentation-derived milk proteins continues to accelerate.
Companies Entering the Space
Several biotech firms worldwide are now developing fermentation‑derived human milk proteins:
- All G (Australia): Producing human beta‑casein and lactoferrin to help formula more closely resemble breast milk.
- Guoke Xinglian (China): Engineering bioidentical human milk glycoproteins, starting with lactoferrin, backed by $14.6M in Series A funding.
- Helaina and TurtleTree: Both working on fermentation‑derived lactoferrin for infant formula, supplements, and women’s health products.
These proteins are positioned for use in formula, functional nutrition, and immune‑support supplements.
Technical Challenges
While producing isolated proteins is feasible, recreating the complexity of human milk remains difficult. A major hurdle is glycosylation, the sugar structures attached to proteins that influence stability, digestion, and immune function.
“Replicating human-like glycosylation is extremely challenging,” Medo said, noting that glycosylation patterns shift based on lactation stage, maternal health, and infant needs. Fermentation systems can mimic certain structures, but not the full diversity or dynamic changes found in nature.
Other challenges involve how proteins behave within milk’s broader matrix. For example, beta‑casein forms micelles that interact with fats and minerals during digestion—interactions hard to reproduce in isolated form.
Safety and Regulation
As startups push to commercialize fermentation‑derived human milk proteins, regulatory questions are rising. Many companies plan to use the FDA’s GRAS pathway, which allows ingredients deemed safe by experts to enter the market.
Medo argues that biologically active proteins may require deeper scrutiny:
“Lactoferrin is not a simple nutrient; it affects gene expression, immunity, and microbial balance,” she said. “In any other context, these activities would be classified as a biologic.”
Recent global infant formula recalls involving cereulide toxin contamination have heightened safety concerns around manufacturing standards. While fermentation may eventually improve production models, adding biologically active proteins could introduce new regulatory complexity.
“The smallest and most fragile infants deserve the highest standard of care,” Medo emphasized.
Explore the Agenda
Discover forward-looking sessions on novel bioactives, clinical validation strategies, global regulatory pathways, formulation challenges, and commercial scale-up shaping the future of infant nutrition
Partner With Us
Connect with senior R&D, regulatory, and commercial leaders across ingredient providers, formula manufacturers, and foodtech companies seeking innovative, evidence-backed solutions to accelerate safe market entry
Join Industry Leaders
Network with decision-makers and innovators defining the next generation of clinically validated regulatory-ready ingredients designed to narrow the gap between formula and human breast milk